Targocid 400 mg or. opl. (pdr. + oplosm.)/inj. opl. (pdr. + oplosm.)/inf. opl. (pdr. + oplosm.) i.v./i.m. flac. بلجيكا - الهولندية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

targocid 400 mg or. opl. (pdr. + oplosm.)/inj. opl. (pdr. + oplosm.)/inf. opl. (pdr. + oplosm.) i.v./i.m. flac.

sanofi belgium sa-nv - teïcoplanine 400 mg - poeder en oplosmiddel voor oplossing voor injectie; poeder en oplosmiddel voor oplossing voor infusie; poeder en oplosmiddel voor drank - 400 mg - teïcoplanine 400 mg - teicoplanin

Tavanic 500 mg filmomh. tabl. بلجيكا - الهولندية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tavanic 500 mg filmomh. tabl.

sanofi belgium sa-nv - levofloxacinehemihydraat 512,46 mg - eq. levofloxacine 500 mg - filmomhulde tablet - 500 mg - levofloxacinehemihydraat 512.46 mg - levofloxacin

Dupixent الاتحاد الأوروبي - الهولندية - EMA (European Medicines Agency)

dupixent

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - middelen voor dermatitis, met uitzondering van corticosteroïden - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Frisium 10 mg tabl. بلجيكا - الهولندية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

frisium 10 mg tabl.

sanofi belgium sa-nv - clobazam 10 mg - tablet - 10 mg - clobazam 10 mg - clobazam

Frisium 20 mg tabl. بلجيكا - الهولندية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

frisium 20 mg tabl.

sanofi belgium sa-nv - clobazam 20 mg - tablet - 20 mg - clobazam 20 mg - clobazam

Lasix 500 mg tabl. بلجيكا - الهولندية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

lasix 500 mg tabl.

sanofi belgium sa-nv - furosemide 500 mg - tablet - 500 mg - furosemide 500 mg - furosemide

Tavanic 5 mg/ml inf. opl. i.v. flac. بلجيكا - الهولندية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tavanic 5 mg/ml inf. opl. i.v. flac.

sanofi belgium sa-nv - levofloxacinehemihydraat 51,246 mg/ml - eq. levofloxacine 5 mg/ml - oplossing voor infusie - 5 mg/ml - levofloxacinehemihydraat 51.246 mg/ml - levofloxacin

Tavanic 5 mg/ml inf. opl. i.v. flac. بلجيكا - الهولندية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tavanic 5 mg/ml inf. opl. i.v. flac.

sanofi belgium sa-nv - levofloxacinehemihydraat 51,246 mg/ml - eq. levofloxacine 5 mg/ml - oplossing voor infusie - 5 mg/ml - levofloxacinehemihydraat 51.246 mg/ml - levofloxacin

Tazko 5 mg - 5 mg tabl. verl. afgifte بلجيكا - الهولندية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

tazko 5 mg - 5 mg tabl. verl. afgifte

sanofi belgium sa-nv - felodipine 5 mg; ramipril 5 mg - tablet met verlengde afgifte - 5 mg - 5 mg - felodipine 5 mg; ramipril 5 mg - ramipril and felodipine

Eloxatin 5 mg/ml inf. opl. (conc.) i.v. flac. بلجيكا - الهولندية - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eloxatin 5 mg/ml inf. opl. (conc.) i.v. flac.

sanofi belgium sa-nv - oxaliplatine 5 mg/ml - concentraat voor oplossing voor infusie - 5 mg/ml - oxaliplatine 5 mg/ml - oxaliplatin